Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — H1 FY2021 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, June 2025
Slide 1: Suven Pharma Earnings Presentation Q2 & H1FY21
SUVEN PHARMA Earnings Presentation Q2 & H1FY21
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q2FY21 3
Slide 4: Operation & Financial Performance Q2 FY21
Operation & Financial Performance Q2 FY21 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other Ser vices 161.73 298.55 154.85 44.84 269.05 206.78 25 144.17 68.22 19.9 54.32 13.21 Q2FY20 Q2FY21 H1FY20 H1FY21 Q2FY20 Q2FY21 H1FY20 H1FY21 Q2FY20 Q2FY21 H1FY20 H1FY21 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot
Financial Snapshot Q2FY21 H1FY21 Growth in Growth in Growth in Revenue EBITDA PAT -14.59% -24.50% -20.35% 0.73% -8.12% -10.44% 6
Slide 7: Key Ratios Q2FY21
Key Ratios Q2FY21 Q2FY20 EBIT to EBITDA to PAT to Income Income Income 38.42% 41.58% 31.16% 45.05% 47.03% 33.41% 7
Slide 8: Key Ratios H1FY21
Key Ratios H1FY21 H1FY20 EBIT to EBITDA to PAT to Income Income Income 41.96% 44.98% 34.38% 47.01% 49.32% 38.67% 8
Slide 9: Financials Q2FY21
Financials Q2FY21 Revenue EBIDTA PAT EPS 2,784 1,309 930 915 3.7 3.6 1,178 2,440 2,377 741 2.9 989 RUPEES MN RUPEES MN RUPEES MN RUPEES Q2FY20 Q1FY21 Q2FY21 Q2FY20 Q1FY21 Q2FY21 Q2FY20 Q1FY21 Q2FY21 Q2FY20 Q1FY21 Q2FY21 9
Slide 10: Financials H1FY21
Financials H1FY21 Revenue EBIDTA PAT EPS 2,358 1,849 4,782 4,817 7.3 2,167 1,656 RUPEES MN RUPEES MN RUPEES MN RUPEES 6.5 H1FY20 H1FY21 H1FY20 H1FY21 H1FY20 H1FY21 H1FY20 H1FY21 10
Slide 11: Financials Q2FY21
Financials Q2FY21 EBITDA Margin (%) PAT Margin (%) 47% 48% 42% 38% 33% 31% Q2FY20 Q1FY21 Q2FY21 Q2FY20 Q1FY21 Q2FY21 11
Slide 12: Financials H1FY21
Financials H1FY21 EBITDA Margin (%) PAT Margin (%) 49% 45% 39% 34% H1FY20 H1FY21 H1FY20 H1FY21 12
Slide 13: Financial Table – Q2 & H1FY21
Financial Table – Q2 & H1FY21 Quarter ended Period ended 30-Sep-20 30-Jun-20 30-Sep-19 30-Sep-20 30-Sep-19 Revenue 2,377.45 2,439.72 2,783.73 4,817.16 4,782.09 EBITDA 988.50 1,178.47 1,309.31 2,166.97 2,358.44 EBITDA Margin 41.58% 48.30% 47.03% 44.98% 49.32% EBIT 913.50 1,107.83 1,253.96 2,021.33 2,
Slide 14: Company Background
Company Background _———z ist oom
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Revenues, EBITDA and Consolidated process research & across the entire CDMO PAT of Rs 4817 Mn, Rs 2166 Mn and deve
Slide 17: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven Pharmaceuticals provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since
Slide 18: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers An integrated research service provider with Leveraging on unmatched capabilities Present across the research capabilities to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers
Business Drivers Over 90% of Working with revenues from innovator companies regulated in developed markets markets Long term having stringent regulations – commercial supply opportunity with reflection of our research skills Repeat business the launch of owing to long product by global standing spon
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 24: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — H1 FY2021 Earnings Presentation on 6ix